Long-Term Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple Sclerosis

被引：0
|
作者：
Rubin, David T. [1 ]
Cree, Bruce A. C. [2 ]
Wolf, Douglas C. [3 ]
Alekseeva, Olga [4 ]
Charles, Lorna [5 ]
Petersen, AnnKatrin [5 ]
Sheffield, James K. [5 ]
Cheng, Chun-Yen [5 ]
Riolo, Jon V. [5 ]
Silva, Diego [5 ]
Lublin, Fred D. [6 ]
Cohen, Jeffrey A. [7 ]
Danese, Silvio [8 ]
机构：
[1] Univ Chicago Med, Ctr Inflammatory Bowel Dis, Chicago, IL USA
[2] Univ Calif San Francisco, Weill Inst Neurosci, San Francisco, CA USA
[3] Atlanta Gastroenterol Associates, Ctr Crohns Dis & Ulcerat Colitis, Atlanta, GA USA
[4] Nizhny Novgorod Reg Clin Hosp, Nizhnii Novgorod, Nizhegorod, Russia
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Mt Sinai Med Ctr, New York, NY USA
[7] Cleveland Clin, Mellen Ctr MS Treatment & Res, Cleveland, OH USA
[8] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Lombardia, Italy
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2023年 / 118卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S911
引用
收藏
页码：S680 / S680
页数：1
相关论文
共 50 条
  • [21] Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely Active ulcerative colitis: PURSUIT-SC long-term extension
    Reinisch, W.
    Gibson, P.
    Sandborn, W. J.
    Feagan, B.
    Marano, C.
    Strauss, R.
    Johanns, J.
    Zhang, H.
    Padgett, L.
    Adedokun, O. J.
    Colombel, J. -F.
    Collins, J.
    Rutgeerts, P.
    Tarabar, D.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S248 - S249
  • [22] Predictors of time to relapse upon ozanimod withdrawal in patients with moderately to severely active ulcerative colitis
    Vermeire, S.
    Abraham, B.
    Bressler, B.
    Reinisch, W.
    Axelrad, J. E.
    Jain, A.
    Memaj, A.
    Akukwe, L.
    Liu, W. J.
    Osterman, M. T.
    Canavan, J. B.
    Sands, B. E.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 882 - 884
  • [23] Malignancy Rates With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials
    Hartung, H-P.
    Cree, B. A. C.
    Selmaj, K. W.
    Havrdova, E. K.
    Comi, G.
    Sheffield, J. K.
    Minton, N.
    Lindholm, A.
    Ding, N.
    Bar-or, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 330 - 331
  • [24] Concomitant Administration of Ozanimod and Serotonergic Antidepressants in Patients With Ulcerative Colitis or Relapsing Multiple Sclerosis
    Regueiro, Miguel
    Siegmund, Britta
    Horst, Sara
    Moslin, Ryan
    Charles, Lorna
    Petersen, AnnKatrin
    Tatosian, Daniel
    Wu, Hsiuanlin
    Lawlor, Garrett
    Fischer, Monika
    D'Haens, Geert
    Colombel, Jean-Frederic
    INFLAMMATORY BOWEL DISEASES, 2024,
  • [25] Golimumab for moderately to severely active ulcerative colitis
    Kedia, Saurabh
    Ahuja, Vineet
    Makharia, Govind K.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (10) : 1273 - 1282
  • [26] Guselkumab for moderately to severely active ulcerative colitis
    不详
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2025, 10 (02): : 112 - 112
  • [27] SAFETY OF LONG-TERM OZANIMOD TREATMENT FOR UP TO 4 YEARS BY AGE GROUP IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: AN INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
    Siegel, Corey A.
    Rubin, David T.
    Long, Millie D.
    Danese, Silvio
    Cross, Raymond K.
    Armuzzi, Alessandro
    Dignass, Axel
    Kobayashi, Taku
    Faye, Adam S.
    Lama, Sonie
    Charles, Lorna
    Cetin, Volkan
    Petersen, AnnKatrin
    Wu, Hsiuanlin
    Wang, Dong
    Jain, Anjali
    Sabino, Joao
    GASTROENTEROLOGY, 2024, 166 (05) : S805 - S806
  • [28] Filgotinib for moderately to severely active ulcerative colitis
    Mannucci, Alessandro
    D'Amico, Ferdinando
    El Saadi, Ahmad
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2022, 16 (10) : 927 - 940
  • [29] Low Rate of Infections With Long-term Use of Ozanimod in Relapsing Multiple Sclerosis Trials
    Hartung, Hans-Peter
    Cree, Bruce A. C.
    Selmaj, Krzysztof W.
    Havrdova, Eva Kubala
    Comi, Giancarlo
    Sheffield, James K.
    Minton, Neil
    Janjua, Anne
    Ding, Ning
    Bar-Or, Amit
    NEUROLOGY, 2020, 94 (15)
  • [30] Safety, Efficacy, and Pharmacokinetics of Golimumab in Patients with Moderately to Severely Active Ulcerative Colitis: PURSUIT-SC Long term Extension
    Reinisch, Walter
    Gibson, Peter R.
    Sandborn, William
    Feagan, Brian G.
    Marano, Colleen
    Strauss, Rick
    Johanns, Jewel
    Zhang, Hongyan
    Padgett, Lakshmi
    Adedokun, Omoniyi J.
    Colombel, Jean-Frederic
    Collins, Judith
    Rutgeerts, Paul J.
    Tarabar, Dino
    GASTROENTEROLOGY, 2016, 150 (04) : S776 - S777
12345